Takeda's Latest Investment Reflects Long-Term Shift In R&D Strategy
Executive Summary
The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.
You may also be interested in...
Takeda's Investments In Data Science Seek Improved Trial Outcomes, R&D Efficiency
President of R&D Andrew Plump notes that much of the work to rationalize Takeda's pipeline after its Shire acquisition took place years ago when the Japanese pharma streamlined its R&D organization, but investments in data science to improve clinical trial outcomes and R&D efficiency are ongoing.
Takeda's Weber: ‘Everything Relies On Our Ability To Deliver Innovative Medicines’
With the formal completion of its huge acquisition of Shire now just a day away, some eight months after it was first announced, Takeda CEO presses home what he sees as the key priorities and benefits of the combined operation - but the real work to realize these is just beginning.
Takeda gains novel drug discovery tech through Envoy acquisition
Takeda's late 2010 research alliance with Envoy Therapeutics has led to the Japanese firm acquiring 100% of the privately held US CNS drug discovery specialist for up to $140 million in cash, in a deal expected to be finalized within the next few days.